| Target | Acquirer | Price |
|---|---|---|
| Pharmaceuticals | ||
| R-Pharm US LLC | Ixempra® | N/A |
| AbbVie Inc. | Rights to a Priority Review Voucher | $350 million |
| Valeant Pharmaceuticals International | Sprout Pharmaceuticals, Inc. | $1 billion |
| Raptor Pharmaceuticals Corp. | Quinsair™ | $68.4 million |
| Novartis AG | Remaining rights to ofatumumab | $300 million |
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
